{"_id": "64ffe4ae748b29c10bbbeaef", "and": [{"$or": [{"cancer type": "breast cancer"}, {"cancer type": "gastric adenocarcinoma"}, {"cancer type": "gastroesophageal junction adenocarcinoma"}, {"cancer type": "colorectal cancer"}]}, {"$or": [{"HER2 amplification/overexpression": true}, {"uterine serous carcinoma": true}, {"HER2-mutated gastric adenocarcinoma": true}, {"HER2-mutated gastroesophageal junction adenocarcinoma": true}]}, {"$and": [{"HER2-directed therapy": false}, {"hypersensitivity to drug formulation": false}, {"exposure to cumulative dose of anthracyclines": false}, {"recent treatment or participation in another clinical trial": false}]}], "nctId": "NCT04579380", "title": "A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations"}